Literature DB >> 26527820

Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method.

Fusako Miyamoto1, Kumi Kawaji1, Shinya Oishi2, Nobutaka Fujii2, Mitsuo Kaku3, Eiichi N Kodama4.   

Abstract

BACKGROUND: Direct comparison of enzymatic and original blue cell-counting detections with the multinuclear activation of an indicator (MAGI) cells, so far, remains to be performed in parallel. Although inhibitors for reverse transcription solely inhibit the reverse transcription step, those for HIV-1 entry block syncytium formation of HIV-1-infected MAGI cells in addition to the entry (dual inhibition). It raises a concern that reduction of enzymatic activity is artificially influenced by syncytium-blocking activity of inhibitors for entry.
METHODS: The MAGI cells with a syncytium inducible strain, HIV-1IIIB, were used for anti-HIV activity determination both with conventional counting with X-Gal staining and measurement of chlorophenol red β-d-galactopyranoside conversion with a plate reader.
RESULTS: Infectivity of HIV-1 in the MAGI cells was highly correlated with both methods. In microscopic observation, small blue cells with single or a couple of nuclei were dominantly observed in the presence of inhibitors for entry, but not in the presence of those for reverse transcription. Actual anti-HIV-1 activities were comparable or moderately sensitive in the chlorophenol red β-d-galactopyranoside method.
CONCLUSIONS: Antiviral activities of inhibitors for entry obtained from both enzymatic and counting methods appear to be comparable, even in infection of a highly syncytia inducible HIV-1IIIB strain.
© The Author(s) 2015.

Entities:  

Keywords:  Enzyme; entry inhibitor; reverse-transcriptase inhibitor; screening; sensitivity

Mesh:

Substances:

Year:  2015        PMID: 26527820      PMCID: PMC5890520          DOI: 10.1177/2040206615614164

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  14 in total

1.  4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.

Authors:  E I Kodama; S Kohgo; K Kitano; H Machida; H Gatanaga; S Shigeta; M Matsuoka; H Ohrui; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.

Authors:  Akira Otaka; Miki Nakamura; Daisuke Nameki; Eiichi Kodama; Susumu Uchiyama; Syota Nakamura; Hiroaki Nakano; Hirokazu Tamamura; Yuji Kobayashi; Masao Matsuoka; Nobutaka Fujii
Journal:  Angew Chem Int Ed Engl       Date:  2002-08-16       Impact factor: 15.336

3.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.

Authors:  Shinya Oishi; Saori Ito; Hiroki Nishikawa; Kentaro Watanabe; Michinori Tanaka; Hiroaki Ohno; Kazuki Izumi; Yasuko Sakagami; Eiichi Kodama; Masao Matsuoka; Nobutaka Fujii
Journal:  J Med Chem       Date:  2008-01-16       Impact factor: 7.446

5.  Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.

Authors:  Hiroki Nishikawa; Shota Nakamura; Eiichi Kodama; Saori Ito; Keiko Kajiwara; Kazuki Izumi; Yasuko Sakagami; Shinya Oishi; Tadayasu Ohkubo; Yuji Kobayashi; Akira Otaka; Nobutaka Fujii; Masao Matsuoka
Journal:  Int J Biochem Cell Biol       Date:  2008-09-10       Impact factor: 5.085

6.  Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.

Authors:  Y Maeda; D J Venzon; H Mitsuya
Journal:  J Infect Dis       Date:  1998-05       Impact factor: 5.226

7.  Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

Authors:  K Maeda; K Yoshimura; S Shibayama; H Habashita; H Tada; K Sagawa; T Miyakawa; M Aoki; D Fukushima; H Mitsuya
Journal:  J Biol Chem       Date:  2001-07-13       Impact factor: 5.157

8.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.

Authors:  Kazuki Izumi; Kumi Kawaji; Fusasko Miyamoto; Kazuki Shimane; Kazuya Shimura; Yasuko Sakagami; Toshio Hattori; Kentaro Watanabe; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Mitsuo Kaku; Stefan G Sarafianos; Eiichi N Kodama
Journal:  Int J Biochem Cell Biol       Date:  2013-01-26       Impact factor: 5.085

10.  2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.

Authors:  Atsushi Kawamoto; Eiichi Kodama; Stefan G Sarafianos; Yasuko Sakagami; Satoru Kohgo; Kenji Kitano; Noriyuki Ashida; Yuko Iwai; Hiroyuki Hayakawa; Hirotomo Nakata; Hiroaki Mitsuya; Eddy Arnold; Masao Matsuoka
Journal:  Int J Biochem Cell Biol       Date:  2008-04-11       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.